BeyondSpring (BYSI) Accounts Payables (2015 - 2026)
BeyondSpring (BYSI) posted Accounts Payables of $646000.0 for Q1 2026, up 77.96% sequentially from $363000.0 in Q4 2025, and up 80.45% YoY from $358000.0 in Q1 2025.
BeyondSpring (BYSI) Accounts Payables (2015 - 2026) Analysis & Trends
BeyondSpring has reported Accounts Payables for 12 years, with the latest figure at $646000.0 in Q1 2026.
- Quarterly Accounts Payables rose 80.45% year-over-year to $646000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646000.0 (up 80.45% YoY) and the FY2025 annual result came in at $363000.0, up 23.05% from the prior year.
- Accounts Payables rose to $646000.0 in Q1 2026 per BYSI's latest filing, from $363000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $2.1 million in Q2 2024 and troughed at $266000.0 in Q2 2025.
- A 5-year average of $786818.2 and a median of $561000.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables sank 87.45% in 2025, then surged 80.45% in 2026.
- Over 5 years, Accounts Payables stood at $1.1 million in 2022, then sank by 48.1% to $561000.0 in 2023, then plunged by 47.42% to $295000.0 in 2024, then gained by 23.05% to $363000.0 in 2025, then surged by 77.96% to $646000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $646000.0, $363000.0, and $304000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 790,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 790,000.00 |
| Mar 31, 2026 | 646,000.00 |
| Dec 31, 2025 | 363,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 266,000.00 |
| Mar 31, 2025 | 358,000.00 |
| Dec 31, 2024 | 295,000.00 |
| Jun 30, 2024 | 2.12 Mn |
| Dec 31, 2023 | 561,000.00 |
| Jun 30, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | 2.13 Mn |
| Jun 30, 2021 | 2.15 Mn |
| Mar 31, 2021 | 1.57 Mn |
| Dec 31, 2020 | 2.22 Mn |
| Sep 30, 2020 | 2.19 Mn |
| Jun 30, 2020 | 1.95 Mn |
| Mar 31, 2020 | 5.14 Mn |